Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Xylem, Inc. — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B), while Xylem, Inc. trades at $103.66 (market cap $23.99B). The key difference: Xylem, Inc. is far larger — about 4.8× Travere Therapeutics Inc. Common Stock's market cap, and Xylem, Inc. pays a 1.67% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Xylem, Inc. for 51 Days on average.
| TVTX | XYL | |
|---|---|---|
Market Cap | $5.02B | $23.99B |
Volume | 2,060,842 | 2,429,384 |
Sector | Health | Industrials |
52-Week High | $67.52 | $152.95 |
52-Week Low | $26.79 | $100.92 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $5.15B | $25.77B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Xylem (XYL) trades at $102.54, down slightly by 0.05% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results due October 27, 2026. Revenue has grown from $5.5B in 2022 to $9.04B in 2025, with net income margins improving to 10.59%. Recent developments include a $1.5B senior note offering to fund acquisitions of Cornell Pump and Roper Pump, alongside a new CFO appointment.
The outlook is supported by steady revenue growth, margin expansion, and strategic acquisitions in water technology, though near-term sentiment is cautious due to technical weakness and China-related headwinds. Risks include execution of acquisitions and debt increase, but analyst consensus price target of $146.63 implies significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
